Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Hemolytic uremic syndrome and encephalopathy from Shiga toxin–producing Escherichia coli

Toru Ishihara and Hideki Ozawa
CMAJ July 22, 2019 191 (29) E817; DOI: https://doi.org/10.1503/cmaj.190155
Toru Ishihara
Division of General Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Ozawa
Division of General Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

A 60-year-old Japanese woman was admitted to hospital for impaired consciousness and convulsive status epilepticus. She had received supportive care for bloody diarrhea at a nearby hospital 9 days earlier. Blood test results at admission were as follows: white blood cell count, 43.5 (normal 4.0–10.0) × 109/L; hemoglobin, 99 (normal 120–150) g/L; platelet count, 23 (normal 150–400) × 109/L; lactate dehydrogenase, 1306 (normal 110–240) U/L; and creatinine, 137.9 (normal 50–90) μmol/L. The other blood test results were unremarkable. Colonoscopy showed mucosal hyperemia and edema, and computed tomography showed generalized thickening of the colonic wall (Figure 1A, B). A stool culture tested positive for Shiga toxin–producing Escherichia coli O157. Diffusion-weighted and T2-weighted fluid-attenuated inversion recovery magnetic resonance imaging (MRI) showed symmetric high signals in the thalamus (Figure 1C), basal ganglia, insular cortex, external capsule and subcortical occipital lobe (Figure 1D). High signals were observed in the pons and periphery of the fourth ventricle (see video, Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190155/-/DC1). The patient was diagnosed with hemolytic uremic syndrome and encephalopathy associated with Shiga toxin–producing E. coli. She was treated with anti-epileptic drugs and ventilator management in the intensive care unit (ICU); given the severity of her neurologic symptoms, she received hemodialysis and plasma exchange. Her general condition improved, and she was discharged from the ICU on day 13.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

(A) Colonoscopy image in a 60-year-old woman with hemolytic uremic syndrome from Shiga toxin–producing Escherichia coli, showing mucosal hyperemia, marked edema and red areas of hemorrhage, indicating hemorrhagic colitis. (B) Computed tomography image showing generalized thickening of the colonic wall, particularly in the ascending colon (target sign, arrow). (C, D) Diffusion-weighted and T2-weighted fluid-attenuated inversion magnetic resonance images of the brain showing symmetric high signals indicating encephalopathy associated with hemolytic uremic syndrome.

The incidence of infection with Shiga toxin–producing E. coli is estimated to be about 2.8 million acute cases annually, with about 4000 cases complicated by hemolytic uremic syndrome.1 The transmission route is oral, through consumption of contaminated food and water. Involvement of the central nervous system affects mortality. 2 Abnormal findings associated with encephalopathy in hemolytic uremic syndrome are usually found bilaterally, in the thalamus and pons.3 Our patient showed a wide range of abnormal findings, and the differential diagnosis included toxic metabolic encephalopathy (e.g., from hypoxia or hypoglycemia). Brain MRI does not provide a definitive diagnosis but is useful to diagnose encephalopathy and select treatment. Timely plasma exchange may be helpful to treat encephalopathy associated with Shiga toxin–producing E. coli.4

A video of magnetic resonance imaging of the patient’s brain is available in Appendix 1, at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190155/-/DC1.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

References

    1. Majowicz SE,
    2. Scallan E,
    3. Jones-Bitton A,
    4. et al
    . Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis 2014;11:447–55.
    1. Torres AG,
    2. Amaral MM,
    3. Bentancor L,
    4. et al
    . Recent advances in shiga toxin-producing Escherichia coli research in Latin America. Microorganisms 2018;6: E100.
    1. Magnus T,
    2. Röther J,
    3. Simova O,
    4. et al
    . The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 2012; 135: 1850–9.
    1. Schwartz J,
    2. Padmanabhan A,
    3. Aqui N,
    4. et al
    . Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149–62.

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire